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Abstract
Background: Point-of-care tests have the capacity to improve healthcare delivery by reducing costs and delay
associated with care. A novel point-of-care immunochromatographic test for dual diagnosis of both HIV and syphilis
by detecting IgG, IgM and IgA antibodies to HIV, and specific and recombinant Treponema pallidum antigens has
recently been developed, but has not been evaluated in rural field settings. We evaluated the performance of the
SD Bioline Syphilis/HIV Duo (Duo) assay at a healthcare center in rural Uganda.
Methods: A convenience sample of pregnant women attending Kinoni Health Centre IV from March to May, 2013
was enrolled. Venous blood was collected and centrifuged for plasma isolation. Samples were tested with the Duo
assay and compared with the Treponema pallidum hemaglutination assay and paired HIV rapid antibody tests as
the reference standards. The ease of use and time required for the Duo assay were also assessed by laboratory
technicians.
Results: Two hundred twenty women were enrolled with a mean age of 25.00 years (SD 5.41). The sensitivity and
specificity of the Duo assay were 100% (95% CI 79.0 – 100%) and 100% (95% CI 97.6 – 100.0) respectively, for
syphilis, and, 100% (75.9 – 100%) and 99.5% (96.8 – 99.9%) respectively, for HIV. The duo kit was found to be faster
and easier to use than the current HIV and syphilis testing techniques.
Conclusion: The sensitivity and specificity of the SD Bioline HIV/Syphilis Duo test were excellent in a field setting in
Uganda. The Duo assay should be further evaluated in alternate populations and with point-of-care specimens (e.g.
whole blood from finger stick specimens), but shows promise as a tool for improved HIV and syphilis surveillance,
diagnosis, and treatment in field settings.
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Background
Syphilis is a curable infectious disease, estimated to in-
fect 12 million people annually, [1], including an esti-
mated 1.4 million pregnant women, [2]. The prevalence
is highest in low income settings, where syphilis preva-
lence among pregnant women ranges as high as 17% [1].
Untreated maternal syphilis during pregnancy is a par-
ticularly critical public health problem because the infec-
tion can cause adverse birth outcomes in 60-80% of
children born to infected women, including stillbirth,
premature birth, neonatal death, low birth weight, con-
genital syphilis and disability [1]. Early screening for and
treatment of syphilis during pregnancy can effectively
prevent adverse birth outcomes [3]. However, fewer
than half of pregnant women receive ante-natal syph-
ilis testing in many low resource settings, [4], likely
d u ei np a r tt oc o s ta n di n f r a s t r u c t u r er e q u i r e do fc l a s -
sic syphilis assays [5].
Similarly, while an estimated 1.5 million pregnant
women giving birth each year are HIV infected, only ap-
proximately 35% are tested for HIV [6]. Early accurate
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cornerstone of prenatal care and central to effective pre-
vention of mother-to-child transmission (MTCT) of
HIV [6]. In addition, syphilis infection during pregnancy
greatly increases the risk of MTCT of HIV [7].
The World Health Organization (WHO) has recom-
mended the dual elimination of MTCT HIV and syphilis,
with new strategies and integrated monitoring and
evaluation activities [8]. Screening for HIV and syphilis
are recommended as part of a comprehensive dual elim-
ination strategy [9]. Moreover, integrating rapid syphilis
screening and HIV testing for pregnant women has been
found to be feasible, cost-effective, and effective in pre-
venting MTCT of syphilis and HIV [10]. However, while
many countries have adopted policies recommending in-
tegration, comprehensive implementation has not been
achieved [10].
Conventionally, conducting concurrent HIV and syphilis
tests require two separate diagnostic modalities: a
point-of-care HIV serology assay and a laboratory-
based non-treponemal assay or, where available, a
second point-of-care syphilis assay. Recently, the SD
Bioline Syphilis/HIV Duo Assay (Duo), a rapid, lateral
flow assay has been developed to concurrently test for
both syphilis and HIV. The assay is designed to detect
IgG, IgM and IgA antibodieso fb o t hs y p h i l i s( t r e p o -
nemal serology) and HIV. The test costs $2US dollars
per kit, can be performed by non-laboratory personnel,
and takes approximately 20 minutes to complete. In-
corporation of both tests in a single kit has potential
advantages, including decreased needle use and blood
volume, eliminating the need for laboratory personnel
or infrastructure, decreased time to results, and lower-
ing diagnostic testing costs. However, the dual assay
has not been tested in rural field settings.
We evaluated the performance of the Duo assay at a
pre-natal clinic in rural Uganda. We used the Trepo-
nema pallidum haemaglutination assay (TPHA) and the
Uganda HIV screening algorithm [11] as reference stan-
dards. The goal of this study was to assess the diagnostic
accuracy of this test using venous samples prior to
evaluation of its feasibility and accuracy as a point-
of-care tool.
Methods
We conducted a cross-sectional study in Kinoni Health
Centre IV, Mbarara, Uganda, from March to May, 2013.
Venous blood samples were collected into EDTA tubes
from a convenience sample of pregnant women attend-
ing clinic for routine prenatal clinical care.
The study was approved by the faculty research ethics
committee (FREC) Mbarara University of Science and
Technology and the study participants provided written
informed consent.
All procedures were completed by laboratory techni-
cians at the Kinoni Health Center. Whole blood samples
were centrifuged at 1300rcf for 5 minutes and plasma
was separated. We followed the manufacturer’s instruc-
tions to test plasma samples with the Duo assay (Standard
Diagnostics, Inc. Yongin, Gyeonggi, South Korea). Briefly,
20 μl of plasma and three drops of buffer were added to
the sample area. Results were read by two independent la-
boratory technicians after 20 minutes.
For our reference standards we used the Treponemal
pallidum hemagluttination assay (TPHA) for syphilis
and the series method of the national HIV testing algo-
rithm [12], for HIV. In brief we tested all samples
serially with 1) the Determine HIV-1/2/O assay (Abbott
Laboratories, Abbott Park, IL), 2) the HIV 1/2 Stat-Pak
Ultra Fast (Chembio Diagnostic Systems, Medford, NY)
and 3) the Uni-Gold Recombinant HIV-1/2 (Trinity Bio-
tech, Bray, Ireland) assay. A negative first assay was con-
sidered negative. A positive first assay was followed by a
second assay for confirmation. A third test was per-
formed for discordant results between the first two tests.
We calculated the sensitivity and specificity, and corre-
sponding 95% confidence intervals (95% CI) of both
components of the Duo assay using Stata Version 12.0.
We also calculated the frequency of indeterminate re-
sults. We also assessed the ease of use and time required
for the Duo assay.
Results
Two hundred twenty women were enrolled with a mean
age of 25.00 (SD 5.41). Of the 220 study participants’ sam-
ples tested, antibodies against T. pallidum,H I V ,a n d ,b o t h
were detected in 19 (8.6%) (Table 1), 16 (7.3%) (Table 2)
and 3 (1.4%), respectively. The sensitivity and specificity of
the Duo kit (Table 3) was 100% (95% CI 79.0 – 100%) and
100% (95% CI 97.6 – 100%) for syphilis, and, 100% (95%
CI 75.9 – 100) and 99.5% (95% CI 96.8 – 99.9%) for HIV.
The Duo kit took approximately 25 minutes to perform in
the laboratory. The test results were read by two different
laboratory technicians and they both found it easy to use
by way of assessing amount of sample manipulation in-
volved. There was 100% inter-reader agreement for both
the HIVand syphilis results.
Table 1 Positive and negative tests of SD BIOLINE HIV/
syphilis Duo kit for syphilis
TPHA test
Positive Negative
HIV-syphilis
duo results
Positive (%) 19 0 19 (8.6)
Negative (%) 0 201 201 (91.4)
Total (%) 19 201 220 (100)
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The sensitivity (100%) and specificity (100%) for syphilis,
and sensitivity (100%) and specificity (99.5%) for HIV, of
the Duo HIV and syphilis lateral flow assay were excel-
lent when tested with a population of women attending
routine maternal care in southwestern Uganda. These
data provide proof of principle for feasibility and accur-
acy of this assay in similar settings. If our findings are
corroborated in larger studies and with point-of-care
specimens, they could support broad use of the assay to
facilitate diagnosis of both HIV and syphilis in resource-
constrained settings with minimal human resource or la-
boratory capacity.
Prior studies have shown similar results. A large (n =
2336), multinational study demonstrated a sensitivity of
99.91% and 99.67% and specificity of 99.67% and 99.72%
for HIV and syphilis, respectively [13]. A notable differ-
ence between that study and ours was that the assay was
performed in centralized laboratories. Two other recent
reports from California, USA and England using ar-
chived specimens noted sensitivities and specificities
above 99.5% for both assays [14,15]. Our study contrib-
utes a validation of the assay at a peripheral health cen-
ter in a resource-limited setting and adds to the growing
evidence in support of the high accuracy of the assay
across various settings.
Although we performed our tests in a laboratory set-
ting, the assay was found to be quicker (approximately
25 minutes), easier to use, and cheaper (approximately
$2USD versus $2USD for TPHA and $3-10USD for
the HIV algorithm) than the current techniques for
HIV and syphilis testing/screening. Moreover, running
the tests separately adds a requirement for additional
time, costs, and human resources. Lastly, we found no
indeterminate results and inter-reader agreement was
found to be 100%. Further evaluation of these results
with whole blood specimens will be important to con-
firm the feasibility and ease of use of the assay.
The HIV prevalence reported in our study is comparable
to that reported by the Uganda AIDS Indicator Survey
(8.3%, [16]). In contrast, we estimated a considerably lower
prevalence of syphilis than other national estimates [17].
This difference might have been due to local differences in
syphilis rates, or recent improvement in syphilis testing and
treatment programs in Uganda [10]. In spite of the similar
or lower prevalence obtained in this study, the HIV, syphilis
and HIV-syphilis co-infection rates are still alarming and
signal an urgent need to improve efforts to prevent, detect
and treat syphilis and HIV in similar populations.
The most important limitation of this study was the use
of venous blood which was centrifuged and tested in a la-
boratory as opposed to point-of care whole blood speci-
mens obtained from a figure prick. We did so to
determine the best-case diagnostic accuracy of the assay
prior to a more extensive point-of-care evaluation of test
feasibility, ease of use, and accuracy. Even without point-
of-care evaluation, our results do offer promising data on
the use of the Duo kit in centers that do have laboratory
capacity, based on its ease of use, time to results, and ac-
curacy. Our study was also performed in a single center
and on a specific patient population. Larger, multicenter
studies will help broaden the generalizability of our results.
Conclusion
The continuing worldwide syphilis and HIV epidemics
and their resultant impact on both maternal and child
health warrants increased attention to prevention and de-
livery of high quality syphilis and HIV care. Rapid, low-
cost assays that can be incorporated into public health
programs in resource-constrained settings are an import-
ant step in this process. We found that the Duo kit had
excellent performance with venous specimens from
women accessing prenatal care in rural Uganda. The test
should be further evaluated with point-of-care whole
blood specimens obtained from a finger prick and in
broader populations, but shows promise as an additional
tool for improved HIV and syphilis surveillance, diagnosis,
and treatment in similar settings.
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Table 3 Summary of the validity and reliability of SD
BIOLINE HIV/syphilis Duo kit
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV (95% CI) NPV (95% CI)
Syphilis (%) 100.0
(79.1 - 100.0)
100.0
(97.7 - 100.0)
100.0
(79.1 - 100.0)
100.0
(97.7 - 100.0)
HIV* (%) 100.0
(75.9 - 100.0)
99.5
(96.9 - 99.9)
94.1
(69.2 - 99.7)
100.0
(97.7 - 100.0)
TPHA – Treponema pallidum hemagglutination assay; HIV algorithm - Determine,
Statpak and UniGold tests run serially; Duo kit – SD BIOLINE HIV/syphilis duo kit.
*HIV-syphilis results were obtained from TPHA and HIV algorithm results.
Table 2 Positive and negative tests of SD BIOLINE HIV/
syphilis Duo kit for HIV
HIV algorithm
Positive Negative
HIV-syphilis
duo results
Positive (%) 16 1 17 (7.7)
Negative (%) 0 203 203 (92.3)
Total (%) 16 204 220 (100)
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